Takeda has joined forces with Iambic Therapeutics on a multiyear collaboration to use the US biotech's AI-driven, structure-based drug discovery platform to find new therapies for gastrointestinal and ...
Love culture? Sign up to our free newsletter for all the essential shows, compelling books, must-see films, and live performances that you need to know about here. Stephen SamuelsonSports Editor ...
Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a deal that could exceed $1.7bn. The Takeda-Iambic AI drug ...
Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon Feb 9 (Reuters) - Privately held Iambic said on Monday it has entered a ...
Feb 9 (Reuters) - Privately held Iambic said on Monday it has entered a multi-year partnership worth more than $1.7 billion with Japan's Takeda Pharmaceutical (4502.T), opens new tab to use artificial ...
After sharing word that it would be prioritizing artificial intelligence to aid discovery work, Takeda Pharmaceuticals has inked a multiyear deal to access Iambic Therapeutics' broad suite of drug ...
Iambic’s physics-informed NeuralPLexer is intended to enhance protein–ligand modeling, enabling broader exploration of chemical modalities and improving hit-to-lead efficiency for difficult-to-drug ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Japan’s largest drug company is teaming up with an ...
Three researchers wearing blue lab coats in a laboratory Iambic uses both physics- and AI-based machine learning models. Credit: Iambic Therapeutics Iambic Therapeutics, a San Diego–based start-up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results